Company: MYSEW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004290
Chunk: 31

Company: Myseum, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 31
---
 of the acquired business onto our
    platform and contract terms, including disparities in the revenue, licensing, support or professional services model of the acquired
    company;

    ●
    diversion of management’s attention from
    other business concerns;

    ●
    adverse effects to our existing business relationships
    with business partners and customers as a result of the acquisition;

    ●
    the potential loss of key employees;

    ●
    use of resources that are needed in other parts
    of our business; and

    ●
    use of substantial portions of our available
    cash to consummate the acquisition.

In addition, a significant portion of the purchase
price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment
at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating
results based on this impairment assessment process, which could adversely affect our results of operations.

Acquisitions could also result in dilutive issuances
of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business
fails to meet our expectations, our operating results, business and financial position may suffer.

If research analysts do not publish research
about our business or if they issue unfavorable commentary or downgrade our common stock or Series A Warrants, our securities’
price and trading volume could decline.

The trading market for our securities may depend
in part on the research and reports that research analysts publish about us and our business. If we do not maintain adequate research
coverage, or if any of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business,
the price of our common stock and Series A Warrants could decline. If one or more of our research analysts ceases to cover our business
or fails to publish reports on us regularly, demand for our securities could decrease, which could cause the price of our common stock
and Series A Warrants or trading volume to decline.

We may issue additional equity securities,
or engage in other transactions that could dilute our book value or relative rights of our common stock, which may adversely affect the
market price of our common stock and Series A Warrants.

Our board of directors may determine from time
to time that it needs to raise additional capital by issuing additional shares of our common stock or other securities. Except as otherwise
described in this Annual Report on Form 10-K